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Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer in male subjects in Western countries. The
widespread use of prostate-specific antigen (PSA) has increased the detection of this cancer form in earlier stages. Moreover, it has
increased the need for new diagnostic procedures to be developed for patient stratification based on risk of progression. We
analysed laser-microdissected prostate tumour tissue from 43 patients with histologically verified PCa, using the new high-resolution
Affymetrix Mapping 50K single-nucleotide polymorphism array. The results showed six major loss of heterozygosity regions at
chromosomes 6q14–16, 8p23–11, 10q23, 13q13–21 and 16q21–24 and a novel region at chromosome 21q22.2, all of which
reveal concomitant copy number loss. Tumour development was further characterised by numerous novel genomic regions almost
exclusively showing copy number loss. However, tumour progression towards a metastatic stage, as well as poor differentiation, was
identified by specific patterns of copy number gains of genomic regions located at chromosomes 8q, 1q, 3q and 7q. Androgen
ablation therapy was further characterised by copy gain at chromosomes 2p and 10q. In conclusion, patterns of allelic imbalance were
discovered in PCa, consisting allelic loss as an early event in tumour development, and distinct patterns of allelic amplification related
to tumour progression and poor differentiation.
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Prostate cancer (PCa) is one of the most commonly diagnosed
male malignancies in Western countries, and a leading cause of
cancer-related death (Landis et al, 1999).
The widespread use of prostate-specific antigen (PSA) in the
diagnosis of PCa has increased the detection of this cancer in
earlier stages. Although this development has increased the
possibilities to cure patients with PCa, the morbidity of the
disease has equally increased and has pushed the demand for
stratification of treatment for patients with PCa. Because PCa often
progresses slowly, a subset of patients with early-stage disease may
be candidates for watchful waiting rather than surgical treatment.
Currently, it is impossible to discriminate between latent and
aggressive cancers at an early state of disease. Furthermore,
clinicians cannot predict how slowly or rapidly a cancer will grow,
or whether a cancer has the potential to metastasise. Development
and progression of PCa from a localised disease to hormone-
refractory and metastatic stage is driven by a multistep process
with accumulation of multiple genetic and epigenetic changes in
specific genes (Quinn et al, 2005). Altered transcript levels in
cancer genomes are often related to copy number changes (Pinkel
and Albertson, 2005), and genome-wide detection of allelic
imbalance in cancer tissue by polymorphic genetic markers has
become an important technique to identify genetic events involved
in the aetiology and progression of human cancers (Balmain et al,
2003). Until recently, the technology represented by PCR-based
determination of microsatellites only allowed a modest number of
polymorphic markers to be used, which limited the resolution of
the technique. With the development of comparative genomic
hybridisation (CGH) arrays using more than 30000 BAC clones
spanning the human genome (Ishkanian et al, 2004), and high-
density single-nucleotide polymorphism (SNP) microarrays de-
signed to genotype more than 100000 SNPs in the human genome
DNA (Matsuzaki et al, 2004), the resolution of the whole genome
scanning technique has increased considerably and allowed
accurate and reproducible determination of copy number changes
in the cancer genome (Goyama et al, 2004; Nannya et al, 2005). The
SNP array offers the possibility to analyse LOH and generate
accurate copy number simultaneously in a high-throughput and
high-resolution genome-wide manner, thus making it possible to
distinguish between LOH regions with underlying hemizygous
deletions and those with copy-neutral events (Zhao et al, 2004).
The identification of genomic areas showing copy loss is highly
dependent on sampling of pure tumour DNA without contamina-
tion of normal epithelium, stroma and/or inflammatory cells (Zhao
et al, 2004). We therefore performed laser microdissection to
obtain pure samples of prostate adenocarcinoma, and Affymetrix
SNP arrays were applied to 43 phenotypically well-characterised
PCas spanning from localised PCa to metastatic disease with and
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swithout previous androgen deprivation. In the present study, we
report results based on an array with more than 50000 SNPs, and
this remarkable increase in resolution defined distinct patterns
of chromosomal loss confined to PCa development and patterns
of chromosomal gains confined to PCa progression and poor
differention (Gleason score X8).
MATERIALS AND METHODS
Sample collection and clinical data
Samples of prostate adenocarcinoma were selected from series of
patients with PCa who underwent surgery for their disease at the
Department of Urology, Skejby Sygehus during the periods 1994–
1996 and 2003–2004. The tissue was isolated as either chips from
transurethral resection of the prostate (TURP) from patients with
metastatic PCa who received palliative treatment or as four needle
biopsies (gauge 12–14), two from each lobe obtained during
surgery for radical prostatectomy, from patients with histologically
verified PCa. The tissue was stored either as fresh frozen or
‘Tissue-Tek’-embedded tissue and stored at  801C until examina-
tion. All cases were reviewed by a qualified uropathologist. The
sections were examined and areas of adenocarcinoma were
identified. In approximately 40% of the patients, the biopsies did
not contain adenocarcinoma tissue, and these patients were
therefore excluded from the study. Blood samples were obtained
from patients with PCa and frozen as a source of normal germline
DNA. In total, 87 samples were analysed: 43 samples of DNA from
PCa tissue and 44 samples of germline DNA from blood samples.
Of these samples, 39 were matched germline and cancer DNA.
Clinicopathological data were obtained from the medical records.
The study protocol was approved by the ethical committee in the
Aarhus Council.
Laser microdissection of prostate adenocarcinoma
In brief, 5mm thin sections of prostate tissue were cut on a cryostat
and placed on PALM
s membrane slides. After haematoxylin
staining (Sigma Aldrich-Denmark, Brondby, Denmark) for 3min,
the samples were rinsed in H2O and stained in eosin (Sigma
Aldrich) for 10s. After rinsing the slides in H2O, they were
dehydrated in increasing concentrations of ethanol and air-dried
for 10min. Prostate adenocarcinoma cells were isolated by laser
microdissection using the PALM system (PALM Microlaser
Technologies AG, Bernried, Germany). An area of approximately
10–30mm
2 was dissected from each patient and isolated in 300ml
of lysis buffer (Gentra Systems Inc., Minneapolis, MN, USA).
DNA extraction
DNA was extracted using of the PureGene DNA extraction kit
(Gentra Systems Inc., MN, USA) (www.gentra.com). A 10ml
volume of Proteinase K (5mgml
 1) was added to the lysis buffer.
Protein precipitate solution was added and the sample was
centrifuged. The supernatant was isolated and 1ml of linear
polyacrylamid (10mgml
 1) and 300ml of isopropanol were added.
The sample was centrifuged, the supernatant was discharged and
the DNA pellet was washed in 70% ethanol. The supernatant was
discharged and the dried pellet was rehydrated in 15mlo f
rehydration solution. On average 500ng to 1mg DNA was obtained
from each sample.
Spectophotometric absorbance was measured at 260 and
280nm. Ratios (OD260/OD280) of 1.470.2 (mean7standard devia-
tion (s.d.)) were obtained for DNA extracted from laser-micro-
dissected PCa tissue and ratios of 1.870.1 were obtained for blood
DNA.
GeneChip
s mapping 50K array
Array experiments were performed according to the Affymetrix
GeneChip Mapping 50K array standard protocol (Affymetrix Inc.,
Santa Clara, CA, USA). The Mapping 50K system consists of two 8-
mm arrays each designed to hybridise labelled PCR fragments from
XbaI- and HindIII-cleaved DNA. To reduce the costs of the project,
only the array containing probes for XbaI-cleaved DNA detecting
58960 SNPs was used. A 250ng measure of DNA was used for
the Mapping 50K array. We obtained a call rate of 92.977%
(mean7s.d.) in the tissue samples and 96.174.5% in the germline
samples, thus comparable to the call rates of the previous
generation of SNP array Mapping 10K from Affymetrix (Koed
et al, 2005).
Data analysis
The physical position of all SNPs (n¼58960). on the Mapping
100K array was mapped according to the May 2004 genome
assembly (hg17) at http://genome.ucsc.edu/
Single-nucleotide polymorphisms that did not map or mapped
to more than one position in the genome assembly were excluded
from the analysis, leaving 57429SNPs.
DNA analysis software (GDAS) 3.0.2 Patch Software (Affymetrix
Inc., CA, USA) was used to generate genotype calls. Genotypes and
probe intensities derived from germline and cancer DNA were
loaded into the software package dChip (http://www.dchip.org/)
(Lin et al, 2004), which was used for LOH analysis: the probe
intensities were normalised and a single signal value (the observed
signal) for each SNP in each array was obtained. Loss of
heterozygosity calls were obtained for the 39 samples for which
matched tumour and germline DNA exist.
Validation of SNP genotypes
The accuracy of SNP genotype calls generated by the Affymetrix
GDAS 3.0.2 software was evaluated by comparison with genotyping
obtained independently by a single-base extension method using
the ABI PRISM
s SNaPshott Multiplex kit (Applied Biosystems,
Foster City, CA, USA) as previously described (Gaustadnes et al,
2006). A list of all the primers used for PCR amplification and
single-base extension SNP genotyping is shown in Supplementary
Information (Table 1). The DNA samples were similar to the
samples used for SNP Chip analysis.
Quantitative PCR
Real-time PCR was performed on an ABI PRISM
s 7000 Sequence
Detection System (Applied Biosystems, Foster City, CA, USA),
using the SYBR
s GREEN PCR Master Mix (Applied Biosystems).
Quantification of four different target genes (MAP3K7, PPP3CC;
SGCZ and CSMD1) was based on standard curves constructed
from four-fold serially diluted normal genomic DNA samples. The
copy number of each target was determined relative to a reference
Line-1 repetitive element, with a method previously described by
others in detail (Zhao et al, 2004). A complete list of primer
sequences is given in Supplementary Information (Table 2).
Mann–Whitney non-parametric test was used to determine the
difference in copy number between groups. GrapaPad Prism4 (San
Diego, CA, USA) was used as statistical software.
Extraction of weighted signal intensities
After normalisation and extraction of signal values for the 87
arrays (43 tumours and 44 germline samples), as described in Data
analysis, the data were further normalised SNP-wise to allow
comparison between different SNPs. Signal values are not directly
comparable because probe sets representing different SNPs on the
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sarray have different physical properties. Therefore, the data were
normalised SNP-wise using the mean and s.d. of the germline
samples, that is, zij¼(xij meanj)/s.d.j, where xij is the observed
signal of SNP j in sample i (germ line or tumour), and meanj and
s.d.j are the mean and standard deviation of SNP j for all 44
germline samples. As a consequence, the mean and s.d. of zij is 0
and 1, respectively, for all the SNPs in the germline samples. To
further reduce the noise level in the signal values, we calculate the
average of M¼9 SNPs weighted by genomic distance; that is,
aij¼Szi(jþl) exp( dj(jþl))/Sexp( dj(jþl)), where the sum (S)i s
over the four neighbouring SNPs on both sides of SNP j
(l¼ 4, 3,y,0,y,3,4) and dj(jþl) is the genomic distance
between SNP j and jþl. aij is referred to as the weighted signal
intensity – in the following referred to as signal intensities.
Mapping of genomic regions commonly showing copy
number alterations
Genomic regions commonly showing copy number alterations
were identified as segments of consecutive SNPs, for which the
average weighted signal intensity (over all tumour samples) was
significantly different from the average weighted signal intensity of
the germline samples (Pp0.01). Only regions of X40 consecutive
SNPs, each with Pp0.01, were reported. The null distribution of
germline samples was obtained by randomly permuting the array
labels (tumour and germ line) 10000 times and computing the
difference in averages for each permutation.
Genomic differences between tumour subgroups
For different subgroups of tumours that were defined by
metastasis status, tumour stage or androgen deprivation status,
the differences were identified based on weighted signal intensities.
For each subgroup, the average weighted signal intensity was
calculated and plotted. The significance of the difference of the
group means was calculated using a permutation test. Group labels
were randomly shuffled 10000 times, the difference recalculated
and the number of times a value larger/smaller than the observed
group difference was counted. Note: the group labels were
reassigned sample-wise and not SNP-wise, such that the depen-
dencies between SNPs were maintained. To assess the significance
of the observed pattern of differences, it was evaluated how often
the observed segments of SNPs were found in the distribution
obtained by permuting group labels. Segments with Pp0.01 were
reported. At this level, it is expected that less than one
chromosome (22 0.01¼0.22) show a significant segment of
SNPs. An upper bound to the false discovery rate of chromosomes
with reported significant segments is thus 1/no. of chromosomes
with significant segments.
RESULTS
Comparison of genotype calls
Forty-three microdissected tissue samples of PCa and 44
samples of germline DNA from patients with PCa (Table 3;
Supplementary Information) were analysed for allelic imbalance
and copy number alterations using the Mapping 50K SNP chip
from Affymetrix.
In order to validate the genotype calls from the Affymetrix
GDAS software, we compared the genotype call from five
individual SNPs in a total of 114 alleles in five different genes
from Affymetrix GDAS software to the ABI SNaPshot single base
extension method (Gaustadnes et al, 2006). We found a 98%
concordance between the genotype calls in Affymetrix GDAS
software, and by SnaPshot
s single base extension. Two alleles
were inconclusive by SNaPshot SBE. This indicates a high degree
of consistency of the genotype call derived from the Affymetrix
GDAS software. A list of genes is shown in Supplementary Table 4.
Genomic regions commonly showing LOH
The conversion of a heterozygous SNP in normal blood cells to a
homozygous SNP in tumour tissue indicates the loss of one allele
(LOH) in the tumour. The overall pattern of LOH in the 39 samples
of prostate adenocarcinoma, as determined by dChip software,
is shown in Figure 1, Table 1 and Figure 4 (Supplementary
Information). The genomic areas showing frequent LOH were
defined as areas showing LOH in more than 30% of samples (X12
of 39 cases). The regions that range in size from 1.5 to 22.1Mb
include positions at 6q, 8p, 10q, 13q and 16q. The highest
percentage of LOH (460%) was confined to a 1.5-Mb region at
chromosome 8p21.3. The high-resolution SNP array also provides
an excellent tool for discovering novel alterations. One novel
region of frequent recurrent deletion, at 21q22.2, was of particular
interest, because ERG and TMPRSS2, both of which are located at
this region, were recently found to be involved in common gene
fusion events in PCa (Tomlins et al, 2005). This novel LOH region
covering 2.9Mb at chromosome 21q22.2 showed LOH in 12 of the
samples.
Genomic regions commonly showing copy number
alterations
Regions commonly showing copy number alterations were
identified by comparing the signal intensities from the Mapping
50K array in the tumour group (n¼43) with the intensities of the
44 germline samples. Using a cutoff of X40 consecutive SNPs each
displaying significant difference (Pp0.01) between prostate
tumour and germline samples, we identified 73 genomic regions.
The size of the regions extended from 0.5 to 9.6Mb (Table 2). Out
of the 73 regions identified, only two regions at chromosomes 2q24
and 20q13.3 showed a gain. Multiple regions at chromosomes 2, 5,
6, 8, 10, 13, 16 and 18 sharing losses are not necessarily
independent regions of altered DNA copy changes, but could be
subfractions of larger regions.
Comparison of LOH and copy number alterations in
tumour DNA
Recently it has been shown that LOH regions in the cancer genome
often show two copies, despite the loss of one allele (Cleton-Jansen
et al, 2004). We therefore tested the correlation between LOH
and signal intensities for all samples showing LOH. As shown in
Figure 2, the major LOH regions at chromosomes 6, 8, 10, 13, 16
and 21 all showed a positive correlation between LOH and
significantly decreased weighted signal intensities. This indicates
that loss of one allele in PCa correlates to a decrease in copy
number. The LOH/signal intensity plot for all chromosomes is
shown in Supplementary Figure 1. We further tested the same
correlation for the subgroups of localised and metastatic PCa to
determine whether mitotic recombination would be found
preferentially in advanced tumours as compared with early stages
as shown in advanced stages of breast cancer (Cleton-Jansen et al,
2004), but no difference in the individual groups was observed
(data not shown).
To validate the results, we determined the copy number score by
real-time PCR for samples showing LOH in four different genes in
LOH regions at chromosomes 8p and 6q.
The results showed a copy number of 1.0170.2 (mean7s.d.)
(n¼30) in tumour DNA as compared with 2.170.2 (n¼28) in
germline DNA. This confirms that copy number loss is evident in
samples showing LOH.
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sGenomic regions of allelic imbalance in subgroups of
tumours showing poor differentiation and in metastatic
disease
In order to identify genomic regions showing significant altera-
tions in copy number changes in subgroups of prostate tumours,
we compared the signal intensities from the Mapping 50K chips.
Genomic regions defined as regions containing consecutive SNPs
each showed a significant difference between groups of Pp0.01.
Two of the samples could not be classified concerning
metastasis status and were excluded. Samples from metastatic
PCa (n¼22) as compared with localised PCa (n¼19) were
characterised by the almost exclusively increased copy number
throughout the genome, including large regions at chromosomes
1q, 8q, 9q, 11q, 12q and 17q, as listed in Supplementary Table 5A.
Out of the 22 regions identified, only one 0.4-Mb region at
chromosome 4p showed decreased copy number in metastatic PCa
as compared with localised disease.
As illustrated in Figure 3, the genomic changes at chromosome
8q are characterised by gain over large regions exclusively in
samples from metastatic PCa, whereas loss of 8p is shared between
samples from localised and metastatic disease. Genomic changes in
all chromosomes in samples from metastatic vs localised PCa are
shown in Supplementary Figure 2. The only major region showing
Chromosome 6
Chromosome 13 Chromosome 16 Chromosome 21
Chromosome 8 Chromosome 10
Figure 1 Loss of heterozygosity in chromosomes 6, 8, 10, 13, 16 and 21 in microdissected prostate cancer tissue as determined by dChip. Loss of
heterozygosity regions (blue), retained regions (yellow) and uninformative (white) covering the genome in 39 individual samples of matched tumour and
germ line. Each column represents one tumour/germline pair. Additionally, along the right-hand side of each figure within the grey shaded box is the average
LOH score for the 39 samples. Cytoband for the individual chromosomes is shown on the left-hand side. Chromosomes 1–22 are shown in Supplementary
Figure 4.
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sa tendency towards lower signal intensities in samples of
metastatic disease as compared with localised disease was the
LOH region at chromosome 6q14–16. Lowering the cutoff P-value
of the individual SNPs from 0.01 to 0.02 showed that the copy loss
of 6q14–16 was statistically more common in metastatic disease
(Po0.05), suggesting a higher frequency of copy loss in the
samples of metastatic disease as compared with organ-confined
disease (data now shown). The group of samples from patients
with metastatic cancers was further divided into groups from
patients who were given (n¼7) or not given (n¼15) androgen
deprivation treatment. Genomic regions at chromosomes 2p21,
2p16 and 10q21 showed significantly increased copy number in the
samples from patients who received androgen ablation therapy
(Table 5B (suppl)+Figure 3 (suppl)).
Similar patterns of exclusively increased copy numbers were
seen from samples displaying a Gleason score X8( n¼23) when
compared with a Gleason score p7( n¼19). Increased copy
numbers at positions 1q32, 7q32, 8q22 and 8q24.1 were shared
between samples from patients with metastatic disease and poorly
differentiated tumour (Gleason score X8) (Table 5C (suppl)).
We further compared the signal intensities for samples from
patients with organ-confined (T2a–c) vs locally invasive tumours
(T3aþb), but no regions reached the cutoff values indicated
above.
3
−3
2
−2
1
−1
0
0 50 100 150
Chromosome 6
SNP position (in Mb)
SNP position (in Mb)
S
i
g
n
a
l
 
i
n
t
e
n
s
i
t
y
3
−3
2
−2
1
−1
0
S
i
g
n
a
l
 
i
n
t
e
n
s
i
t
y
3
−3
2
−2
1
−1
0
S
i
g
n
a
l
 
i
n
t
e
n
s
i
t
y
3
−3
2
−2
1
−1
0
S
i
g
n
a
l
 
i
n
t
e
n
s
i
t
y
3
−3
2
−2
1
−1
0
S
i
g
n
a
l
 
i
n
t
e
n
s
i
t
y
3
−3
2
−2
1
−1
0
S
i
g
n
a
l
 
i
n
t
e
n
s
i
t
y
Chromosome 8 
140 120 100 100 80 60 40 20
SNP position (in Mb)
80 60 40 20
SNP position (in Mb)
SNP position (in Mb)
80 60 40 20 0
SNP position (in Mb)
140 120 100 80 60 40 20 0
Chromosome 10 Chromosome 13
Chromosome 16
15 20 25 30 35 40 45
Chromosome 21
01 0 1 5 2 0 2 5
1.0
0.5
0.0
−0.5
−1.0
c2
c
1
5
Figure 2 Correlation between LOH and genomic copy number alterations in SNPs showing LOH. The signal intensity value for a particular SNP was
calculated for all tumours with LOH in that particular SNP and plotted with a colour that indicates the number of tumours with LOH. Dotted lines
correspond to a significance level of 1%. The widths of these vary because some SNPs experience more LOH than others. Single-nucleotide polymorphisms
with signal intensities outside the 1% significance level threshold are considered to represent genomic copy numbers different from 2 (if positive 42 and if
negative o2). Areas for which LOH and copy number reductions seem to be positively correlated include 6q, 8p, 10q, 13q, 16q and 21q. Inserted colour
code shows number of samples with LOH.
Table 1 Identification of common genomic alterations (LOH) in
prostate cancer
Frequency Position in hg17
a Region size (Mb) Start
a End
a
430%
8
> > > > > > <
> > > > > > :
6q14.2–6q16.3 20.7 83.09 103.77
8p12–8p11.21 12.7 30.49 43.22
10q23.1–10q23.31 6.7 83.73 90.44
13q13.2–13q21.1 22.1 33.69 55.91
16q22.2–16q23.3 11.0 70.05 81.05
21q22.3 2.9 38.91 41.80
440%
8
<
:
6q14.3–6q16.1 11.8 87.30 99.07
8p21.2–8p12 3.7 26.82 30.50
16q23.3–16q24.3 5.2 81.05 86.28
450%
 
8p23.2–8p21.3 21.1 0.20 21.26
8p21.3–8p21.2 4.1 22.73 26.82
460%
 
8p21.3–8p21.3 1.5 21.26 22.73
Loss of heterozygosity in microdissected prostate cancer tissue was determined by
dChip software. Only genomic regions showing a minimum of 30% LOH are listed in
the table.
aThe genomic positions were based on the May 2004 genome assembly
(hg17) of the UCSC human genome browser (http://genome.ucsc.edu/).
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sDISCUSSION
Using the new Mapping 50K SNParray from Affymetrix, we
performed a high-resolution global scale screening for allelic
imbalance in 43 laser-microdissected samples of PCa. The results
showed a set of genomic alterations characteristic to PCa,
consisting of LOH and concomitant copy loss in large regions at
chromosomes 6q, 8p, 10q, 13q and 16q. Most of these affected
regions have previously been associated with PCa (Joos et al, 1995;
Cooney et al, 1996; Elo et al, 1997; Feilotter et al, 1998; Hyytinen
et al, 1999; Lin et al, 2004). However, the increase in resolution
using high-density SNP arrays combined with laser microdissec-
tion enabled us to identify regions that have not previously been
related to this disease, including a 2.9-Mb region showing LOH at
chromosome 21q22.2 in 30% of the samples. Loss of 21q22 has
previously been reported in gastric cancer and NSCLC (Park et al,
2000; Tseng et al, 2005), but the LOH region we discovered in PCa
at 21q22.2 is more distant and therefore previously unknown in
relation to carcinomas. Recently, Tomlins et al (2005) identified a
highly frequent recurrent gene fusion in PCa, including ERG and
TMPRSS at chromosome 21q22, and was recently confirmed by
Yoshimoto et al (2006). Interestingly, ERG and TMPRSS genes are
both located exactly at the outer borders of this new LOH region at
21q22, and support the results showing fusion between these two
genes. During revision of this manuscript, Liu et al (2006) reported
a similar common region of deletion between the ERG and
TMPRSS2 genes on chromosome 21, presumably related to the
recently identified fusion transcripts from these two genes in 25%
of samples of PCa.
Using the signal intensities to determine the significant copy
number changes between tumour and germline samples, addi-
tional regions were identified at chromosomes 2–5, 9, 11, 14, 15,
18 and 20. With a cutoff P-value of 0.01 for X40 consecutive SNPs,
Table 2 Genomic regions with altered signal intensities
Chromosomes Start
a End
a
SNPs in
region
Region
size (Mb) Gain/loss
1 70.31 72.72 77 2.41 Loss
2 40.76 42.08 63 1.32 Loss
2 49.73 50.73 51 1.00 Loss
2 58.12 60.63 64 2.51 Loss
2 67.05 69.07 70 2.02 Loss
2 81.78 82.95 43 1.18 Loss
2 167.63 168.44 44 0.81 Gain
3 75.95 78.11 42 2.17 Loss
4 74.14 75.72 41 1.59 Loss
4 101.42 103.12 42 1.70 Loss
4 142.78 144.48 57 1.70 Loss
4 157.13 158.67 50 1.54 Loss
5 44.28 51.99 65 7.71 Loss
5 88.12 89.87 40 1.75 Loss
5 90.12 92.31 43 2.19 Loss
5 98.57 100.62 48 2.06 Loss
5 100.69 102.38 43 1.68 Loss
5 113.51 115.68 80 2.17 Loss
6 69.21 70.54 54 1.33 Loss
6 75.47 78.16 50 2.68 Loss
6 80.96 82.84 57 1.88 Loss
6 84.03 85.89 66 1.86 Loss
6 87.45 89.36 49 1.92 Loss
6 89.92 94.20 132 4.28 Loss
6 97.38 99.27 46 1.90 Loss
6 99.39 101.86 73 2.47 Loss
6 110.16 113.42 59 3.26 Loss
6 124.66 126.15 55 1.48 Loss
8 0.18 2.76 41 2.58 Loss
8 2.90 4.28 75 1.37 Loss
8 4.47 4.95 54 0.47 Loss
8 4.95 13.61 225 8.66 Loss
8 13.61 23.19 345 9.58 Loss
8 23.42 26.58 78 3.16 Loss
8 26.58 28.16 58 1.58 Loss
8 28.36 30.84 58 2.49 Loss
9 30.09 32.01 44 1.92 Loss
10 57.71 59.11 45 1.40 Loss
10 85.45 86.83 52 1.37 Loss
10 86.94 90.33 67 3.39 Loss
10 91.63 93.03 46 1.40 Loss
10 106.09 109.86 115 3.77 Loss
10 110.09 112.14 42 2.04 Loss
11 113.53 115.20 50 1.67 Loss
13 32.84 36.54 123 3.70 Loss
13 40.07 44.20 122 4.13 Loss
13 44.68 46.13 55 1.45 Loss
13 48.79 51.40 42 2.61 Loss
13 51.59 55.83 103 4.24 Loss
13 59.02 60.10 53 1.07 Loss
13 61.96 63.70 42 1.74 Loss
13 66.67 67.98 56 1.31 Loss
13 82.86 84.22 57 1.37 Loss
13 103.27 104.28 45 1.02 Loss
14 25.10 27.56 55 2.47 Loss
15 47.67 49.27 48 1.59 Loss
16 51.69 53.25 49 1.56 Loss
16 61.10 63.24 61 2.14 Loss
16 72.85 76.17 56 3.32 Loss
16 76.19 78.12 60 1.92 Loss
16 79.68 82.40 64 2.72 Loss
16 82.48 83.24 55 0.75 Loss
16 83.25 85.62 42 2.36 Loss
18 24.47 26.26 54 1.79 Loss
18 28.67 30.80 49 2.13 Loss
18 34.40 36.59 66 2.19 Loss
18 47.67 49.11 52 1.44 Loss
18 50.65 53.59 70 2.93 Loss
18 54.14 57.06 81 2.92 Loss
18 62.51 64.11 64 1.60 Loss
Table 2 (Continued)
Chromosomes Start
a End
a
SNPs in
region
Region
size (Mb) Gain/loss
18 66.15 68.29 73 2.14 Loss
20 54.18 55.45 40 1.27 Gain
21 21.83 22.70 40 0.87 Loss
Listed are regions with X40 consecutive SNPs each displaying significant difference
(Po0.01) in the signal intensity of the prostate tumour samples compared with
germline samples. Multiple regions at chromosomes 2, 5, 6, 8, 10, 13. 16 and 18 are
not necessarily independent regions of altered DNA copy changes, but can be parts
of larger regions. Median intermarkerdistance is 17kb.
aThe genomic positions were
based on the May 2004 genome assembly (hg17) of the UCSC human genome
browser (http://genome.ucsc.edu/).
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Figure 3 Signal intensities in chromosome 8. Genomic differences
between tumour subgroups were identified based on signal intensities. For
each group, the signal intensity was calculated and plotted. The significance
of the difference of the group means was calculated using a permutation
test. Group of metastatic disease (blue) and localised disease (green).
Significance is indicated on top: Pp0.01 (brown), 0.01pPp0.02 (red),
0.02pPp0.05 (orange).
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identified. All regions except for two showed copy loss in the
tumour samples, indicating that development of PCa is char-
acterised almost exclusively by the loss of specific genomic
regions. The majority of the smaller regions represent genomic
regions that have not previously been related to PCa. Combined
global analysis of LOH and genomic copy number data showed
that LOH in PCa correlates positively to copy loss. Our data
showed no signs of uniparental disomy in LOH regions, as
otherwise recently reported to be a common mechanism in
advanced breast cancer (Murthy et al, 2002; Cleton-Jansen et al,
2004), acute myeloid leukaemia (Raghavan et al, 2005), medulla-
blastoma (Langdon et al, 2006) and basal cell carcinomas (Teh
et al, 2005).
Loss of heterozygosity and concomitant copy loss at chromo-
somes 8p, 10q, 13q,16q and 21q were found with an equal
frequency in both localised and metastatic tumours, and were not
associated with tumour stage or grade. The only LOH region that
showed a tendency towards higher degree of copy loss in
metastatic and low differentiated tumours was chromosome 6q16.
Previous reports have indicated that early-stage organ-confined
prostate tumours did not display chromosome-level imbalances,
and that balanced cytogenetic and epigenetic changes could be
responsible for tumour development (Fu et al, 2000; Chu et al,
2003). A combination of microdissection of tumour tissue to
maximise the yield of neoplastic tissue and a new high-resolution
methodology enabled us to show that LOH and copy number loss
have similar frequency in organ-confined and metastatic tumours,
indicating that LOH is an early event in PCa tumour development.
Recently, it has been shown that LOH at chromosomes 6q, 8p and
10q occurs in high-grade PIN lesions (Wang et al, 2001; Wang and
Lai, 2004a,b), which is now accepted as the most likely preinvasive
stage of prostate adenocarcinoma. Ribeiro et al (2006) recently
hypothesised that LOH at 8p and 13q are distinct initiation events
in the carcinogenesis of PCa. Our data do not support this theory
as LOH of the two regions occurs randomly in our samples. On
average, we observed LOH at 3–4 regions in each sample, and
suggest that accumulation of specific genomic losses occurs as
independent events. Although LOH is a common event in PCa,
approximately 13% of our samples (five out of 39) reveal no sign of
LOH, and were thus chromosomally stable. This number is lower
than 31% of samples reported as chromosomally stable using the
CGH technique (Teixeira et al, 2004).
We then investigated the genomic copy number changes in
relation to tumour stage and Gleason grade. Interestingly, the
analysis revealed 31 genomic regions at chromosomes 1, 4, 5, 8–
12, 14, 17 and 19–22, all except one showing significantly
increased copy number in tumours from patients with metastatic
disease as compared with localised disease. The regions identified
at chromosome 8q are similar to the regions recently identified by
high-resolution CGH (van Duin et al, 2005), showing amplification
of 8q harbouring genes like C-MYC and EIF3S3, and gain of 17q25
in advanced cases of PCa (Ribeiro et al, 2006). The region at 5p13
showing copy gain harbours the F-box protein SKP2, which is
upregulated in advanced PCa (Dhanasekaran et al, 2001) and was
found to induce PCa in a transgenic mouse model (Shim et al,
2003). Copy gain at chromosome 11q13 was shown to predict
postoperative recurrence independent of stage and grade, but a
specific biomarker has not been identified at this region (Paris
et al, 2004).
The copy number changes in relation to tumour grade showed a
similar pattern of exclusively upregulation in numerous regions at
chromosomes 1q, 3q, 7q, 8q and 14p in samples displaying high
Gleason grade. There was a considerable overlap to regions
identified also in samples from patients with metastatic PCa at
chromosomes 1q, 7q and 8q. The majority of the regions showing
increase in copy number were novel, and these areas should be
examined for potential oncogenes and their ability to predict the
course of disease in a larger study with long-term follow-up.
Based on the results, we propose a genetic pathway of prostate
carcinogenesis with distinct initiation events, namely loss of
chromosomes 8p, 13q, 16q and 21q. As tumours progress, prostate
carcinomas display increased genomic complexity, leading to
genomic imbalances including loss of 6q and gain at chromosomes
8q, 1q, 7q and 3q, and this enables the tumour to metastasise.
Prospective studies with sufficiently long follow-up time, allowing
for disease survival as the clinical endpoint, are necessary to
determine the clinical use of allelic imbalance as a prognostic
marker.
In conclusion, our analysis revealed a characteristic pattern of
genomic imbalances in adenocarcinoma tissue from patients with
PCa and identified genomic regions highly associated with tumour
initiation, metastasis and high-grade disease. Our results indicate
that allelic loss is an early event in prostate tumour development,
and that allelic amplification is exclusively confined to tumours that
progress. Future studies should evaluate the use of a specific pattern
of genomic allelic imbalances as a prognostic marker in PCa.
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